November 1, 2024 07:06 AM EDTUpdated 08:12 AM
R&D

Es­sa’s shares tank as it looks for op­tions af­ter aban­don­ing prostate can­cer drug

Ayisha Sharma

News Reporter

Es­sa Phar­ma is ex­plor­ing “strate­gic op­tions” as it ends work on its prostate can­cer drug that failed a mid-stage test. The com­pa­ny’s shares $EPIX nose­dived …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bio­gen brings in med­ical chief as CFO plans re­tire­ment; Macro­Gen­ics CEO an­nounces de­par­ture

UCB's an­ti-tau Alzheimer's pro­gram fails Phase 2 pri­ma­ry end­point, but high­lights pos­i­tive sec­on­daries

Q&A with Obe­si­ty So­ci­ety’s CEO as the field pre­pares for next-gen meds

Fol­low­ing 2019 re­jec­tion, FDA ad­comm votes against Lex­i­con's type 1 di­a­betes and CKD drug

Gar­dasil de­mand in Chi­na sinks, and Mer­ck ex­pects the same next quar­ter

‘Im­i­ta­tion is best form of flat­tery’: Re­gen­eron CEO com­ments on Am­gen’s Eylea biosim­i­lar

A service from the Financial Times